Innoviva (INVA) Profit After Tax (2010 - 2026)
Innoviva (INVA) posted Profit After Tax of $186.6 million for Q1 2026, up 250.12% on a QoQ basis from -$124.3 million in Q4 2025, and up 500.56% year-over-year from $31.1 million in Q1 2025.
Innoviva (INVA) Profit After Tax (2010 - 2026) Analysis & Trends
Innoviva's Profit After Tax history runs 17 years deep, the most recent figure standing at $186.6 million for Q1 2026.
- Quarterly Profit After Tax rose 500.56% year-over-year to $186.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $233.0 million (up 403.36% YoY) and the FY2025 annual result came in at $271.2 million, up 1059.22% from the prior year.
- Profit After Tax was $186.6 million for Q1 2026 at Innoviva, up from -$124.3 million in the prior quarter.
- Across five years, Profit After Tax topped out at $288.6 million in Q3 2022 and bottomed at -$124.3 million in Q4 2025.
- A 5-year average of $29.9 million and a median of $2.6 million in 2024 frame the typical range for Profit After Tax.
- Peak annual rise in Profit After Tax reached 3397.12% in 2025, while the deepest fall reached 4880.69% in 2025.
- Innoviva's Profit After Tax stood at -$10.3 million in 2022, then sank by 92.43% to -$19.8 million in 2023, then soared by 113.1% to $2.6 million in 2024, then slumped by 4880.69% to -$124.3 million in 2025, then jumped by 250.12% to $186.6 million in 2026.
- Business Quant data shows INVA's Profit After Tax at $186.6 million in Q1 2026, -$124.3 million in Q4 2025, and $107.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Innoviva | 1.59 Bn | 983.20 Mn | 75.83 Mn | 186.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 186.60 Mn |
| Dec 31, 2025 | -124.30 Mn |
| Sep 30, 2025 | 107.01 Mn |
| Jun 30, 2025 | 63.69 Mn |
| Mar 31, 2025 | -46.58 Mn |
| Dec 31, 2024 | 2.60 Mn |
| Sep 30, 2024 | 3.06 Mn |
| Jun 30, 2024 | -35.88 Mn |
| Mar 31, 2024 | -44.87 Mn |
| Dec 31, 2023 | -19.85 Mn |
| Sep 30, 2023 | 118.19 Mn |
| Jun 30, 2023 | -28.35 Mn |
| Mar 31, 2023 | 34.87 Mn |
| Dec 31, 2022 | -10.31 Mn |
| Sep 30, 2022 | 288.58 Mn |
| Jun 30, 2022 | -24.04 Mn |
| Mar 31, 2022 | 37.86 Mn |
| Dec 31, 2021 | -6.05 Mn |
| Sep 30, 2021 | 323.19 Mn |
| Jun 30, 2021 | 110.85 Mn |